Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo
- Address
- lock Available on a paid plan
Pediatric Inflammatory and Immune-Mediated Diseases
At Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo in Trieste, research in Pediatrics focuses strongly on immune system diseases, digestive system diseases, and musculoskeletal diseases. The trials include children with juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, ulcerative colitis, Crohn's disease, and related inflammatory conditions, with the goal of improving disease control and finding better long-term treatment strategies.
- Testing new therapies for pediatric inflammatory bowel disease and arthritis
- Evaluating treatment effectiveness in chronic immune-mediated conditions
- Supporting safer, more personalized care for children in remission
Several studies also explore macrophage activation syndrome and other severe inflammatory complications, reflecting the site's expertise in complex pediatric immunology.
Pediatric Oncology and Hematology
The site has a major research focus on neoplasms and hemic and lymphatic diseases, especially acute lymphoblastic leukemia, lymphoblastic lymphoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and acute promyelocytic leukemia. These trials are designed to improve survival, reduce relapse, and refine treatment approaches for children and adolescents with high-risk or relapsed cancers.
- Comparing treatment approaches for newly diagnosed and relapsed leukemia
- Studying new combinations to improve cancer control and survival
- Assessing therapies for high-risk solid tumors in children
Research at the Pediatrics Unit also includes immunotherapy and targeted treatment strategies, showing a strong commitment to more effective and less toxic cancer care.
Growth, Metabolic, and Genetic Disorders
Clinical trials here also address nutritional and metabolic diseases and genetic phenomena, including obesity, type 1 interferonopathies, Prader-Willi syndrome, White-Sutton syndrome, Turner syndrome, short stature, and PIK3CA-related overgrowth spectrum. The research aims to improve diagnosis, support growth and weight management, and evaluate targeted treatments for rare pediatric conditions.
- Studying therapies for growth failure and short stature
- Evaluating treatments for pediatric obesity and related metabolic risk
- Exploring targeted care for rare genetic overgrowth and syndromic disorders
This area highlights the site's role in advancing precision medicine for children with complex inherited and developmental conditions.
Respiratory, Infectious, and Supportive Pediatric Care
Another important research stream involves respiratory tract diseases, bacterial infections, and related pediatric complications such as respiratory syncytial virus bronchiolitis and urinary tract infections. These trials aim to improve prevention, shorten illness, and identify more effective and practical treatment options for children.
- Evaluating prevention strategies for RSV-related illness in infants
- Testing optimized antibiotic approaches for febrile urinary tract infections
- Improving care for pediatric respiratory and infectious diseases
The research profile at this hospital/clinic/other health care facility shows a broad pediatric portfolio that combines common childhood illnesses with rare and highly specialized conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 86 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1IRCCS Istituto Giannina Gaslini4active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1IRCCS Istituto Giannina Gaslini4trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo
lock Showing 1 of 41 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Methotrexate | 9 | Unknown | 2017-10-02 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.